Novo Nordisk's stock has stayed near the low end of its yearly range even though the company beat expectations and raised its full year outlook in August, because investors are focused on a rival's weight loss drugs pulling further ahead and on some disappointing results for the company's next big drug candidate.
At the same time, the company's new once a day weight loss pill has become the clear leader among oral treatments in the United States within months of launch and just went on sale in Germany, and the amount of spare cash coming in the door improved sharply in the first half of the year while debt stopped climbing.
The next generation drug that was supposed to close the gap with the rival's best product came up just short of matching it in a head to head study, and a large US government pricing cut for the company's two best selling drugs is coming in 2027.
Putting it together, the current price leans on the bad news more than the good news, so we still see this as undervalued, though less clearly than a simple cheap statistic would suggest.
A quick look at how a few well known investing styles might weigh this stock.
Investors who follow Warren Buffett's approach would note that Novo Nordisk earns a return on equity above 50% and gross margins near 80%, hallmarks of a business with real pricing power built around one widely recognized brand name. But they would also flag that the moat now depends on staying ahead of a well-funded rival's newer drug and on government pricing deals that already cut the US list price of Ozempic from $1,000 to $350 a month, a reminder that even strong brands can lose control of their own pricing.
A Lynch-style investor, who likes businesses an ordinary person can explain in one sentence, would point out that tens of millions of people now take a Novo Nordisk drug every week to manage diabetes or lose weight, real understandable demand rather than a story stock. They would weigh the company's roughly 20% average annual revenue growth over the past three years against a slowing patch, Ozempic sales fell 8% in the most recent quarter, and would want the newer Wegovy pill's strong early prescription numbers to keep climbing before treating the growth story as fully intact.
Investors who follow Philip Fisher's approach of quizzing customers, competitors and former employees before trusting management's own account would zero in on execution under new chief executive Mike Doustdar, who took over in August 2025. They would note that the company's next-generation obesity drug, CagriSema, missed its own weight-loss target and lost a head-to-head trial to a rival's drug, a real test of whether the research pipeline can keep pace with the story management tells about it.
A Cathie Wood-style investor, drawn to treatments that could reshape an entire category of health care, would frame Wegovy and its new pill form as part of a broader shift toward treating obesity as a chronic, drug-treatable condition rather than a lifestyle issue, a market some believe is still in its early innings worldwide. They would also recognize Novo is no longer the market's sole disruptor, since independent estimates now show a rival's obesity drug outselling Wegovy, so the growth case increasingly rests on manufacturing scale and new formulations like the pill rather than the original injectable alone.
Investors who follow Stanley Druckenmiller's approach of sizing positions around clear inflection points would highlight how sharply sentiment has swung here, shares fell 16% in a single day in February 2026 when disappointing trial data on CagriSema came out, layered on top of a leadership change and new US government pricing deals. That kind of volatility around datable catalysts, trial readouts, pricing negotiations, competitor launches, is exactly the setup this style of investor watches for, whether to press a bet or step aside quickly if the trend turns.
These takes are illustrations of well known investing styles applied to this stock. They are informed guesses, not the actual views, statements, or holdings of the people named.
Novo Nordisk's manufacturing build-out and its new once-daily pill are performing as promised, with early prescription and revenue numbers beating expectations and management raising its own sales guidance as a result. But the broader claim to still be the undisputed leader of the obesity-drug category is being tested in real time: its newest drug fell short of its own target and lost a head-to-head trial, an older flagship product is shrinking, and the largest deal it pursued to diversify beyond its core drug went to a rival. The operational picture is genuinely mixed rather than uniformly strong.
In its first quarter after the January 2026 US launch, the oral Wegovy pill logged about 1.3 million prescriptions and 2.26 billion Danish kroner ($353.6 million) in revenue, well above the roughly 1.16 billion kroner analysts had forecast, prompting Novo to raise its 2026 sales and profit guidance. That launch followed billions of dollars in newly committed capacity, including a $4.1 billion second fill-finish plant in Clayton, North Carolina and a 432 million euro tableting expansion in Athlone, Ireland announced in March 2026.
In the head-to-head Phase 3 REDEFINE trial, patients on CagriSema lost 23% of their body weight versus 25.5% for a rival's higher-dose drug, falling short of Novo's own stated 25% target. The stock dropped 16% in a single trading day in February 2026 on the news, and the drug's US regulatory decision, submitted in December 2025, was still pending as of the trial readout.
Independent market trackers now put the split of the branded obesity-drug market at roughly 60% for a competitor's drug versus 40% for Wegovy, and Novo's older diabetes drug Ozempic posted an 8% year-over-year sales decline in the most recent quarter even as the new Wegovy pill and international sales grew.
Novo publicly raised its offer for Metsera to as much as $9 billion in late 2025 but lost the bidding war to a $10 billion Pfizer bid in November 2025 after US antitrust regulators raised concerns about the structure of Novo's proposed deal. No comparable-sized acquisition had closed as of September 2026, though the CEO said in May 2026 the company was looking for deals more than ever.
Based on public evidence such as filings, customer announcements, and delivery records.
Nearly all of its revenue comes from diabetes and obesity medicines built on the same active ingredient, semaglutide, sold as Ozempic and Rybelsus for diabetes and as Wegovy, now available both as a weekly injection and, since January 2026, a daily pill, for weight loss. A smaller share comes from its rare disease business, which sells treatments for hemophilia, growth hormone deficiency and other uncommon blood and hormone conditions.
We'd revisit this call if the price falls below $34.00 or rises above $82.00.
These are review triggers for us to take another look, not price targets or a promise the stock will reach them.
| Metric | NVO (subject) | Peer median |
|---|---|---|
| EV/Sales | 4.98x | 6.29x |
| EV/EBIT | 11.42x | 20.76x |
| EV/EBITDA | 9.82x | 17.11x |
| P/B | 7.39x | 7.17x |
| Gross Margin | 81.0% | 74.3% |
| ROIC | 35.4% | 20.9% |
| ROE | 52.8% | 34.7% |
| Rule of 40 | N.M. | 28.7% |
** FY2025 (ended 2025-12-31): reported sales DKK 309.1bn, net profit DKK 101.0bn. H1 2026 reported sales were DKK 175.3bn (+13% in kroner, +18% CER), net profit DKK 69.5bn (+25%), diluted EPS DKK 15.66 (+25%), though H1 growth was flattered by a one-time, non-cash reversal of a US 340B rebate provision in Q1 2026. Q2 2026 alone: reported sales DKK 78.5bn (+2% reported, +3% CER on an adjusted basis +7% CER), reported operating profit DKK 27.1bn (down 19%) on DKK 6.3bn of non-cash pipeline impairments, net profit DKK 21.0bn (down 21%). Full-year 2026 guidance, raised August 4, 2026, now calls for adjusted sales and operating profit growth of 0% to -6% CER, up from the prior -4% to -12%, still the company's first guided-down year in the GLP-1 era.
** Q2 2026 gross realized US prices continued to compress on rebates; management explicitly guided to a coming US sales decline, citing GLP-1 injectable prescription trends, intensifying competition, and reduced Medicaid coverage. Wegovy injectable Q2 sales were DKK 19.5bn (+1%); the new Wegovy pill added DKK 3.2bn; Ozempic was DKK 31.4bn (+5% CER); Rybelsus (oral Ozempic) fell to DKK 5.2bn (-4% CER). The Obesity and Diabetes Care segment generated DKK 73.6bn of sales at a 38.5% operating margin in Q2; Rare Disease posted an operating loss on impairments.
** Free cash flow improved sharply: H1 2026 was DKK 55.3bn versus DKK 38.4bn in H1 2025, driven by opex phasing, US rebate payment timing, and lower capex, per company disclosure. Trailing-twelve-month free cash flow through Q2 2026 works out to roughly DKK 45bn (about $7.0bn at the current DKK/USD rate), well below the fcf_ttm_after_sbc figure supplied for this run; see input verification below.
** Net debt stabilized: borrowings of DKK 140.1bn against cash of DKK 44.5bn gave net debt of about DKK 95.6bn at June 30, 2026, essentially flat versus DKK 95.4bn at year-end 2025 and a real improvement from the DKK 115.9bn spike at March 31, 2026. The company is also running a DKK 15bn share buyback program (through February 2027); about DKK 8.4bn had been repurchased by late August 2026.
** The Wegovy pill captured about 90% of the US oral obesity market and passed 5 million cumulative prescriptions within 30 weeks of its January 5, 2026 launch (company disclosure, August 2026); it began selling in Germany on September 1, 2026. By contrast, Eli Lilly's rival oral pill Foundayo (orforglipron), approved April 2026, generated only $98 million in Q2 2026 sales.
** Against the explicit large-pharma peer set (LLY, JNJ, ABBV, MRK, AMGN, GILD, PFE, VRTX, BMY, REGN, ZTS), Novo's EV/EBITDA was about 9.8x versus a peer median near 17.1x as of the mid-2026 dataset; the price decline since then likely keeps this gap wide. On a trailing-twelve-month basis through Q2 2026, net profit of roughly DKK 115bn (about $17.9bn) against a market capitalization of roughly $206bn (at the September 2, 2026 close and current share count) implies a trailing price-to-earnings ratio near 11 to 12x, cheap for the sector. Eli Lilly, the direct comparison, held 60.9% of the combined US obesity and diabetes drug market in Q2 2026 versus Novo's 38.8%, with Mounjaro sales up 91% to $9.94bn and Zepbound at $4.93bn, both far outpacing Ozempic and injectable Wegovy growth; Lilly raised its 2026 revenue guidance to $85bn to $87bn.
** Medicare's IRA-negotiated US prices for Ozempic and Wegovy, roughly 71% below current list price, take effect January 2027, a known headwind four months away. Thirteen state Medicaid programs cover GLP-1 drugs for obesity in 2026, down from 16 in 2025 (California, New Hampshire, Pennsylvania and South Carolina dropped coverage in January 2026), with more states reportedly considering removal. In China, the semaglutide compound patent expired in March 2026, though a trade-agreement data-protection provision is expected to delay real generic entry to around April 2027; provincial procurement prices are already down roughly 48% in anticipation.
** Public trackers show only net insider selling over the trailing 90 days (executives as sellers, no purchases recorded), alongside routine equity vesting tied to the company's 100th-anniversary restricted-share program; the the automated screen insider signal was not wired for this run, so this is a secondary, low-weight data point.
** Catalysts: CagriSema FDA decision expected Q4 2026 (filed December 2025, standard review); continued international oral Wegovy pill rollout; buyback and improved free cash flow supporting the balance sheet. Risks: CagriSema missed noninferiority to tirzepatide in the head-to-head REDEFINE 4 trial (announced February 23, 2026, 23% weight loss versus 25.5% for tirzepatide); the ziltivekimab ZEUS cardiovascular outcomes trial failed to reduce cardiovascular events (announced July 31, 2026), triggering a further non-cash impairment due in Q3 2026; the oral obesity candidate monlunabant was terminated in Q2 2026 (DKK 4.0bn write-down); continued share loss to Lilly; further Medicaid coverage attrition; and the January 2027 Medicare price cut.
** See checklist Q6/Q7.
** Reassess bullishly if adjusted CER sales growth turns positive for two consecutive quarters or CagriSema is approved with a workable label. Reassess bearishly if net debt resumes rising past the March 2026 peak or US market share versus Lilly keeps eroding through 2027.
Mechanical model output, a screen, not a fair value.conservative screen, understates growth/AI-capex names
Novo trades around 11 to 12 times trailing earnings and roughly 9 times operating cash profit against a large-pharma peer median in the mid teens to high teens, a discount that still looks too wide given a stabilizing revenue base, a fast-growing oral pill franchise and improved cash generation, even after weighting in real pipeline setbacks and looming 2027 pricing cuts.
Research flagged that one or more mechanical-screen inputs look invalid or distorted (e.g. a data-extraction issue or a capex/FCF definition mismatch); the research verdict was independently re-derived from primary filings, not just a check on the same numbers.
Confidence = 0.7 × research sub-score + 0.3 × mechanical sub-score. Mechanical sub-score rewards the Layer 1 screen for agreeing with Layer 2's direction (corroboration), not just for being conviction=NORMAL in isolation.